Innovative Obesity Treatment Promises High Compliance: Buy Recommendation for Vivani Medical
Here's Why We're Watching Vivani Medical's (NASDAQ:VANI) Cash Burn Situation
Vivani Medical GAAP EPS of -$0.10 Beats by $0.02
Vivani Medical's Regular Industry Conference Presentations Update
10-Q: Q2 2024 Earnings Report
Earnings Flash (VANI) VIVANI MEDICAL Posts Q2 Loss $-0.10
Express News | Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
Express News | Vivani Medical Q2 Operating Expenses USD 5.681 Million
Express News | Vivani Medical Q2 Basic EPS USD -0.1
Express News | Vivani Medical Q2 Net Income USD -5.356 Million
Press Release: Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
Pineapple Financial And 1 Other Stock Under $1 Insiders Are Buying
Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying
Express News | Vivani Medical Shares up 5.6% on Plans to Begin Human Trial for Obesity Implant
Express News | Vivani Medical Inc: Expects to Initiate First Clinical Study Supporting Npm-115 Program in Q4 of 2024
Express News | EXCLUSIVE: Vivani Tells Benzinga 'The NPM-115 Clinical Program Will Consist of a Series of Studies Designed to Support the Development of Vivani's Miniature, 6-month GLP-1 NanoPortalTM Implant for Chronic Weight Management in Obese or Overweight Patients'
Express News | EXCLUSIVE: Vivani Medical Tells Benzinga 'Vivani Expects to Initiate the First Clinical Study Supporting the NPM-115 Program in the Fourth Quarter of 2024'
Express News | EXCLSUIVE: Vivani Medical Tells Benzinga Co. Provides Update On Clinical Development Plans For Miniature, Long-Term, GLP-1 Obesity Implant Program, NPM-115
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
Maxim Group Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $8